DCVAC/OvCa

Drug Profile

DCVAC/OvCa

Alternative Names: Dendritic cell vaccine/Ovarian cancer - Sotio

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator SOTIO
  • Class Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 12 Jan 2016 Phase II development in Ovarian cancer is ongoing in the Czech Republic, Germany and Poland
  • 20 Dec 2013 Phase-II clinical trials in Ovarian cancer (combination therapy, second-line therapy or greater) in Germany (SC)
  • 02 Dec 2013 Phase-II clinical trials in Ovarian cancer (combination therapy, first-line therapy) in Poland (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top